Petros Pharmaceuticals (PTPI) Stock Chart & Stock Price History $0.03 0.00 (-3.51%) As of 03:28 PM Eastern Add Compare Share Share Chart Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Petros Pharmaceuticals Stock Price Performance The Petros Pharmaceuticals (PTPI) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 99.75%, with a year-to-date return of -99.72%. In the past month, the stock has decreased 11.29%, reflecting recent market activity. As of the latest close, Petros Pharmaceuticals traded at $0.03 with a market cap of $888 thousand and volume of 663,479 shares. Receive PTPI Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-1.79%1 Month Performance-11.29%3 Month Performance-97.61%Year-To-Date Performance-99.72%1 Year Performance-99.75% PTPI Stock Chart for Monday, July, 14, 2025 PTPI Chart by TradingView Petros Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/11/2025$0.03$0.03-2.73%$0.03$0.03663,479 shs$888,000.0007/10/2025$0.03$0.03+4.64%$0.03$0.03120,575 shs$913,000.0007/09/2025$0.03$0.03-6.67%$0.03$0.03743,170 shs$872,000.0007/08/2025$0.03$0.03-5.66%$0.03$0.03763,008 shs$935,000.0007/07/2025$0.03$0.03-8.88%$0.04$0.03593,505 shs$991,000.0007/04/2025$0.03$0.03$0.04$0.03245,089 shs$1.09 million07/03/2025$0.03$0.03+0.29%$0.04$0.03245,089 shs$1.09 million07/02/2025$0.03$0.03+6.42%$0.04$0.03491,731 shs$1.08 million07/01/2025$0.03$0.03-2.39%$0.04$0.03266,638 shs$1.02 million06/30/2025$0.04$0.03-5.37%$0.04$0.03265,202 shs$1.04 million Get the Latest News and Ratings for PTPI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 06/27/2025$0.03$0.04+5.99%$0.04$0.03605,999 shs$1.10 million06/26/2025$0.03$0.03+4.37%$0.03$0.03349,548 shs$1.04 million06/25/2025$0.03$0.03+6.67%$0.03$0.03328,165 shs$997,000.0006/24/2025$0.03$0.03-0.33%$0.03$0.03624,658 shs$935,000.0006/23/2025$0.03$0.03+5.99%$0.03$0.03997,598 shs$938,000.0006/20/2025$0.03$0.03+5.19%$0.03$0.03274,634 shs$885,000.0006/19/2025$0.03$0.03$0.03$0.03478,145 shs$841,000.0006/18/2025$0.03$0.03-10.00%$0.03$0.03478,145 shs$841,000.0006/17/2025$0.03$0.03+11.11%$0.03$0.03303,359 shs$935,000.0006/16/2025$0.03$0.03-12.90%$0.03$0.021.30 million shs$841,000.0006/13/2025$0.03$0.03-8.01%$0.03$0.03342,831 shs$966,000.00 Related Companies Soligenix Stock Chart Vaxxinity Stock Chart Polyrizon Stock Chart NovaBay Pharmaceuticals Stock Chart Can-Fite BioPharma Stock Chart CERo Therapeutics Stock Chart InMed Pharmaceuticals Stock Chart 60 Degrees Pharmaceuticals Stock Chart Revelation Biosciences Stock Chart Lipella Pharmaceuticals Stock Chart Receive PTPI Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:PTPI) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
